Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1912 Combined with R-Chemo in B-cell Non-Hodgkin's Lymphoma
NCT06104553Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-A1912 in B-cell non-Hodgkin lymphoma (B-NHL), sponsored by Hengrui Therapeutics. Started Nov 2023; status: recruiting.
02
Drugs
SHR-A1912
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT06104553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06104553.